Guerbet SA
PAR:GBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (9.1), the stock would be worth €12.42 (7% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.5 | €11.6 |
0%
|
| 3-Year Average | 9.1 | €12.42 |
+7%
|
| 5-Year Average | 9.3 | €12.73 |
+10%
|
| Industry Average | 15.8 | €21.58 |
+86%
|
| Country Average | 15.8 | €21.62 |
+86%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Guerbet SA
PAR:GBT
|
146.3m EUR | 8.5 | -1.4 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.9T JPY | 47.5 | 39.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
57B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.2B CHF | 23.9 | 36.1 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
89.7B DKK | 20.6 | 22.6 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.7B USD | 23.7 | 31 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 24.2 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
38B CNY | 31.8 | 23 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
905.8B JPY | 25.5 | 51.2 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -75.9 | -37.9 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.4B USD | -152.6 | -15 |
Market Distribution
| Min | 0.9 |
| 30th Percentile | 10.4 |
| Median | 15.8 |
| 70th Percentile | 25.1 |
| Max | 2 752.4 |
Other Multiples
Guerbet SA
Glance View
Guerbet SA engages in the research, development, manufacture, and sale of contrast products for medical imaging. The company is headquartered in Villepinte, Ile-De-France and currently employs 2,730 full-time employees. The company produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The firm operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
